Dose of Reality

DOSE OF REALITY: FORBES: HOW BIG PHARMA EXPLOITS LOOPHOLES IN THE PATENT SYSTEM

Jun 25, 2024

Avik Roy Highlights How Increased USPTO-FDA Collaboration and Greater Scrutiny Read More

DOSE OF REALITY: FORBES: HOW BIG PHARMA STIFLES COMPETITION WITH PRODUCT SHOPPING

May 23, 2024

Research Column Explores Case Study in Common Patent Abuse Tactic That Read More

DOSE OF REALITY: BIG PHARMA’S PATENT ABUSE BLOCKS COMPETITION IN THE PRESCRIPTION DRUG MARKET, KEEPS DRUG PRICES HIGH

May 21, 2024

Senate Hearing Offers Opportunity to Highlight Market-Based Solutions to Hold Read More

DOSE OF REALITY: STUDY FINDS NEARLY THREE-QUARTERS OF BIG PHARMA’S PATENTS ON TOP-SELLING DRUGS FILED AFTER FDA APPROVAL

May 16, 2024

Analysis Showcases Egregious Scale of Big Pharma’s Patent Thickets on Read More

DOSE OF REALITY: IQVIA REPORT SHOWS HOW BIG PHARMA’S EGREGIOUS PRICING PRACTICES DRIVE INCREASED PRESCRIPTION DRUG SPENDING

May 10, 2024

Analysis Shows Price Hikes Outpacing Inflation, Rising Launch Prices and Read More

DOSE OF REALITY: BIOSIMILAR COMPETITION GENERATES SIGNIFICANT SAVINGS FOR PATIENTS AND THE U.S. HEALTH CARE SYSTEM

May 2, 2024

Reports Find Biosimilars Have Lower Prices Than Brand Name Biologics Read More

DOSE OF REALITY: NEW ANALYSES UNDERSCORE HOW BIG PHARMA’S EGREGIOUS PRICING OF WEIGHT LOSS DRUGS IS UNSUSTAINABLE

Apr 25, 2024

Two Reports Explore Cost for U.S. Patients and the U.S. Health Care System of Read More

Dose of Reality: CBO Confirms Big Pharma’s Egregious Prices on Weight Loss Drugs Are Unsustainable

Mar 22, 2024

CBO Says Cost to Taxpayers of Covering GLP-1 Medications Would Outpace Savings Read More

DOSE OF REALITY: BIG PHARMA CEOS FACE A RECKONING FROM LAWMAKERS AND EXPERTS ON ANTI-COMPETITIVE PRACTICES AND PRICE GOUGING

Feb 12, 2024

Patent Abuse Designed to Extend Monopolies, Block Competition and Keep Prices Read More

DOSE OF REALITY: BIG PHARMA’S EGREGIOUS PRICING PRACTICES AND ANTI-COMPETITIVE TACTICS DRIVE HIGHER HEALTH CARE COSTS

Jan 30, 2024

Big Pharma Price Hikes, Rising Launch Prices And Patent Abuse Impose Massive Read More